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Abstract 
We describe the case of a 65-year-old patient with glossopharyngeal neuralgia. Pain was 
triggered by swallowing, yawning, or cold food. We used the anterior tonsillar pillar 
method for the injection of drugs; a relatively new glossopharyngeal nerve (GPN) block 
which was described by Benumof (Anesthesiology 1991;75:1094–1096). Performing this 
GPN block, daily levobupivacaine (Chirocaine 5 mg/ml) and oral amitriptyline (Laroxyl 
10 mg) were given, as well as methylprednisolone acetate injectable suspension (Depo-
Medrol 40 mg/ml) once only at the beginning of the treatment. A 0–10 point visual 
analogue scale was used daily to evaluate the pain. Pain was successfully controlled with 
a steroid added to the GPN block and orally administered tricyclic antidepressant. We 
think that this treatment is effective for glossopharyngeal neuropathy and could be of 
interest to pain management physicians. 
 
Introduction 
Glossopharyngeal neuropathy is characterized by paroxysms of lancinating or burning 
pain in the oropharynx, whereas vagal neuropathy presents similarly but can also include 
symptoms of vocal cord dysfunction, such as hoarseness. Glossopharyngeal neuralgia is 
estimated to be 75 times less frequent than trigeminal neuralgia [1]. Electromyography 
can be performed to confirm the diagnosis [2].  
In this report, we describe the case of a patient with glossopharyngeal neuralgia. Pain 
was triggered by swallowing, yawning or cold food. 
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Case Report 
A 65-year-old man reported 4 months’ history of paroxysmal pain attacks originating from the right 
lower jaw, disseminating to the right ear region when eating, and also triggered by swallowing, yawning 
and cold food. The duration of the pain attacks were measured in seconds. These pain paroxysms had 
occurred 5 or 6 times daily at the initial stage of the disease. Three months ago, the patient had been 
admitted to the Department of Neurology with complaints of paroxysmal glossopharyngeal pain 
attacks, and hospitalized. During his hospitalization, he received carbamazepine (Tegretol 600 mg p.o. 
daily). 
After a 2-month time period, paroxysmal glossopharyngeal pain attacks gradually recurred and 
increased. The pain attacks were not completely controlled by carbamazepine at a daily dose of 1,200 
mg. The patient was referred to the chronic pain center by a neurologist in a final effort to treat his pain 
before surgery. General physical examination, cardiovascular and neurological examination was normal. 
Magnetic resonance images and magnetic resonance angiography of the brain and brain stem were 
normal; there was no sign of compression on the glossopharyngeal or vagal nerves and also on the brain 
stem. Carbamazepine was stopped. The patient was given a tricyclic antidepressant (amitriptyline 
(Laroxyl) 10 mg/daily p.o.). 
We used the anterior tonsillar pillar (ATP) method, a relatively new glossopharyngeal nerve (GPN) 
block for the injection of drugs, which was described by Benumof [3]. We chose the ATP method, 
because the ATP is easily exposed and tongue movement does not elicit the gag reflex, besides patient 
tolerence is good. In this method, the tongue is swept to the opposite side. A 25-gauge spinal needle is 
inserted 0.5 cm deep, just lateral to the base of the ATP (fig. 1) and 2 ml of levobupivacaine 
(Chirocaine 5mg/ml) is injected on both sides daily. 
We also injected methylprednisolone acetate injectable suspension (Depo-Medrol 40 mg/ml) 20 
mg to each ATP. This was done once only at the beginning of the therapy. The patient was asked to 
evaluate his pain using a 0–10 point visual analogue scale (0 = no pain, 10 = worst possible pain). Over 
the course of 2 weeks after starting the glossopharyngeal block, the patient’s right-sided sore throat and 
pain began to resolve and continued to improve for approximately 1 month. Before starting block 
therapy, the patient had described his pain as 9 on a 10-point scale, whereas after a month of therapy, he 
described it as 1–2 out of 10. The GPN block was stopped at that time; orally administered amitriptyline 
was continued. 
Discussion 
Glossopharyngeal neuralgia was first described by Weisenburg in 1910 [4] in a patient 
with a tumor of the cerebellopontine angle. The cause of this disorder was usually 
undetermined, though in a few reported cases, cerebellopontine angle tumors [5], an 
elongated styloid process or a calcified stylohyoid ligament or the last two together [6] 
were identified as etiological factors. Most of these cases of ‘idiopathic’ glossopharyngeal 
neuralgia are caused by vascular compression of the GPN [7, 8]. 
The other secondary causes of glossopharyngeal neuralgia are Eagle’s syndrome, 
cerebellopontine angle tumors, parapharyngeal space lesions, multiple sclerosis, 
arachnoiditis, posterior fossa arteriovenous malformation, direct carotid puncture, 
metastatic head and neck tumors, and Chiari I malformation [7–11]. 
The paroxysms of pain are triggered by swallowing, particularly cold, salted, bitter, or 
acid foods [6, 12] and by mechanical stimulation of the tonsillar fossa on the affected side 
(trigger zone). 
Local anesthesia of the pharynx and nerve block with mepivacaine (Carbocaine) are 
additional measures that produce temporary benefit [13, 14]. Anticonvulsant treatment  
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(phenytoin) has been advocated as the long-term treatment of choice [15] and 
carbamazepine may also be an alternative to surgical resection of the GPN [9]. 
Several recent studies recommend gabapentin, pregabalin, or a tricyclic antidepressant 
as equivalent first-line agents for treatment of neuropathic pain [12, 16]. Carbamazepine 
is the drug of choice for the initial treatment of neuralgia. In the case of partial pain relief 
with carbamazepine, a second agent can be added or the drug can be changed [17]. 
Gabapentin has been used as a first-line agent or in cases of neuralgia resistant to the 
traditional therapy, with complete or almost total remission in 27% of the cases [18, 19]. 
Gabapentin is considered a second-line medication and definitive scientific evidence of its 
efficacy in the treatment of neuralgia does not exist [18]. 
Our patient’s clinical symptoms of spontaneous paroxysmal burning pain in the 
tonsillar area that radiated to the right ear and did not resolve with previous treatment 
were strongly indicative of glossopharyngeal neuropathy. The patient’s pain was triggered 
by eating, swallowing, yawning, or cold food. Therefore we had to reduce the pain 
quickly, which is why we did not choose gabapentin therapy, since the usage of this drug 
might prolong the total treatment time. The patient used amitriptyline therapy for about 
12 months; during this time, he had no pain attacks. We think a GPN block and steroid 
therapy is more effective in the earlier periods of glossopharyngeal neuropathy and 
amitriptyline is more effective in the later periods of the disease. 
Screening for neuropathic pain is extremely important because misdiagnosis may 
cause unnecessary diagnostic and invasive procedures, increased patient suffering, and 
decreased quality of life. Therefore, patients presenting with lancinating, burning, 
localized throat pain should be evaluated and treated for neuropathic pain if other 
possible causes have been ruled out. Had our patient not come to the pain center, he 
might have undergone potentially unnecessary surgery with no guarantee that his pain 
would have resolved. 
In this case report, we discussed the administration of a GPN block using the ATP 
method, injecting a local anesthetic with steroid, as well as oral amitriptyline usage to 
effectively treat glossopharyngeal neuropathy in a patient. We stress the importance of 
screening patients with unexplained throat pain for pain of neuropathic etiology. The 
mechanism was idiopatic, there was no sign of compression on the GPN region. We 
suggest that this treatment is effective for this kind of glossopharyngeal neuropathy and 
could be of interest to pain management physicians. 
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Fig. 1. The tongue is swept to the opposite side by a laryngoscope. A 25-gauge spinal needle is inserted 
0.5 cm deep, just lateral to the base of the ATP and 2 ml of levobupivacaine (5 mg/ml) is injected on 
both sides. 
 
References 
1  Bruyn GW: Glossopharyngeal neuralgia. Cephalalgia 1983;3:143–157. 
2  Shemirani NL, Halum SL, Merati AL, Toohill RJ, Jaradeh S: Cricopharyngeal electromyography: patterns of 
injury based on etiology. Otolaryngol Head Neck Surg 2007;137:792–797. 
3  Benumof JL: Management of the difficult adult airway. Anesthesiology 1991;75:1094–1096. 
4  Riley HA, German WJ, Wortis H, et al: Glossopharyngeal neuralgia initiating or associated with cardiac arrest. 
Trans Am Neurol Assoc 1942;68:28–29. 
5  Garretson HD, Elvidge AR: Glossopharyngeal neuralgia with asystole and seizures. Arch Neurol 1963;8:26–31. 
6  Graf CJ: Glossopharyngeal neuralgia and ossification of the stylohyoid ligament. J Neurosurg 1959;16:448–453. 
7  Soh KBK: The glossopharyngeal nerve, glossopharyngeal neuralgia and the Eagle’s syndrome. Current concepts 
and management. Singapore Med J 1999;40:659–665. 
8  Ferrante L, Artico M, Nardacci B, Fraioli B, Cosentino F, Fortuna A: Glossopharyngeal neuralgia with cardiac 
syncope. Neurosurgery 1995;36:58–63. 
9  Saviolo R, Fiascanoro G: Treatment of glossopharyngeal neuralgia by carbamazepine. Br Heart J 1987;58:291–
292. 
10  Janetta PJ: Outcome after microvascular decompression for typical trigeminal neuralgia, hemifacial spasm, 
tinnitus, disabling positional vertigo, and glossopharyngeal neuralgia. (Honored Guest Lecture). Clinical 
Neurosurgery 1997;44:331–383. 
11  Cicogna R, Bonomi FG, Curnis A, et al: Parapharyngeal space lesions syncope-syndrome. A newly proposed 
reflexogenic cardiovascular syndrome. Eur Heart J 1993;14:1476–1483. 
12  Dworkin R, Backonja M, Rowbotham MC, Allen R, Argoff C, Bennett G, Bushnell MC, Farrar JT, Galer BS, 
Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk 
DC, Wallace MS, Watkins LR, Weinstein SM: Advances in neuropathic pain: Diagnosis, mechanisms, and 
treatment recommendations. Arch Neurol 2003;60:1524–1534. 
13  Kong Y, Heyman A, Entman ML, et al: Glossopharyngeal neuralgia associated with bradycardia,syncope and 
seizures. Circulation 1964;30:109–113. 
14  Khero BA, Mullins CB: Cardiac syncope due to glossopharyngeal neuralgia. Arch Intern Med 1971;128:806–
808. 
15  Jannone A, Baker AB, Morrell F: Dilantin in the treatment of trigeminal neuralgia. Neurology 1958;8:126–128.  
Case Rep Neurol 2011;3:27–31 
DOI: 10.1159/000324093 
Published online: 
January 21, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–680X 
www.karger.com/crn 
 
 
31
16  Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH: Algorithm for neuropathic pain treatment: An 
evidence based proposal. Pain 2005;118:289–305. 
17  Wiffen PJ, McQuay HJ, Moore RA: Carbamazepine for acute and chronic pain. Cochrane Database Syst Rev 
2005;CD005451. 
18  Wiffen PJ, McQuay HJ, Edwards JE, et al: Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 
2005;CD005452. 
19  Cheshire WP Jr: Defining the role for gabapentin in the treatment of trigeminal neuralgia: a retrospective 
study. J Pain 2002;3:137–142. 